 | • レポートコード：GIR-107A11935 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、NSCLC用標的薬ROS1阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NSCLC用標的薬ROS1阻害剤の種類別市場規模（クリゾチニブ、ロルラチニブ、エントレクチニブ、その他）、用途別市場規模（NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・NSCLC用標的薬ROS1阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roche、Pfizer、Beacon Pharma Limited、Drug International Limted、Incepta Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：クリゾチニブ、ロルラチニブ、エントレクチニブ、その他 ・用途別分析2016年-2026年：NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん ・NSCLC用標的薬ROS1阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・NSCLC用標的薬ROS1阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・NSCLC用標的薬ROS1阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・NSCLC用標的薬ROS1阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・NSCLC用標的薬ROS1阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Targeted Drug ROS1 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Targeted Drug ROS1 Inhibitors for NSCLC size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Targeted Drug ROS1 Inhibitors for NSCLC market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Targeted Drug ROS1 Inhibitors for NSCLC market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Lorlatinib
Entrectinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Targeted Drug ROS1 Inhibitors for NSCLC
1.2 Classification of Targeted Drug ROS1 Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Type in 2020
1.2.3 Crizotinib
1.2.4 Lorlatinib
1.2.5 Entrectinib
1.2.6 Other
1.3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region, (2016-2021)
1.5.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.6 South America Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug ROS1 Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.1.4 Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.2.4 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Beacon Pharma Limited
2.3.1 Beacon Pharma Limited Details
2.3.2 Beacon Pharma Limited Major Business
2.3.3 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.3.4 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Beacon Pharma Limited Recent Developments and Future Plans
2.4 Drug International Limted
2.4.1 Drug International Limted Details
2.4.2 Drug International Limted Major Business
2.4.3 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.4.4 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Drug International Limted Recent Developments and Future Plans
2.5 Incepta Pharmaceuticals
2.5.1 Incepta Pharmaceuticals Details
2.5.2 Incepta Pharmaceuticals Major Business
2.5.3 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.5.4 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Incepta Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.2.3 Market Competition Trend
3.3 Targeted Drug ROS1 Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021)
4.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
5.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2026)
6.2 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2026)
6.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2026)
6.3.2 United States Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.3 Canada Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.4 Mexico Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2026)
7.2 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2026)
7.3 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2026)
7.3.2 Germany Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.3 France Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.5 Russia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.6 Italy Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2026)
8.2 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2026)
8.3 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2016-2026)
8.3.2 China Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.3 Japan Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.4 South Korea Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.5 India Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.7 Australia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2026)
9.2 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2026)
9.3 South America Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2026)
9.3.2 Brazil Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9.3.3 Argentina Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2026)
10.2 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2026)
10.3 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2026)
10.3.2 Turkey Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.4 UAE Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Targeted Drug ROS1 Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021)
Table 5. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 9. Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 13. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 15. Beacon Pharma Limited Major Business
Table 16. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 17. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Drug International Limted Corporate Information, Head Office, and Major Competitors
Table 19. Drug International Limted Major Business
Table 20. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 21. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Incepta Pharmaceuticals Major Business
Table 24. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 25. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021)
Table 27. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Players (2019-2021)
Table 28. Breakdown of Targeted Drug ROS1 Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 29. Targeted Drug ROS1 Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 30. Targeted Drug ROS1 Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 31. Targeted Drug ROS1 Inhibitors for NSCLC New Entrants and Expansion Plans
Table 32. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021)
Table 33. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Type (2016-2021)
Table 34. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Forecast by Type (2021-2026)
Table 35. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021)
Table 36. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Forecast by Application (2021-2026)
Table 37. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 38. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 39. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 40. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 41. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 42. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 43. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 44. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 45. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 46. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 47. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 48. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 49. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 50. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 51. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 52. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 53. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million)
Table 54. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million)
Table 55. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 56. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 57. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 58. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 59. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 60. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 61. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 62. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 63. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 64. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 65. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 66. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Targeted Drug ROS1 Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Type in 2020
Figure 3. Crizotinib
Figure 4. Lorlatinib
Figure 5. Entrectinib
Figure 6. Other
Figure 7. Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application in 2020
Figure 8. Squamous Cell Carcinoma of NSCLC Picture
Figure 9. Adenocarcinoma of NSCLC Picture
Figure 10. Large Cell Carcinoma of NSCLC Picture
Figure 11. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 14. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region in 2020
Figure 15. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Targeted Drug ROS1 Inhibitors for NSCLC Market Drivers
Figure 21. Targeted Drug ROS1 Inhibitors for NSCLC Market Restraints
Figure 22. Targeted Drug ROS1 Inhibitors for NSCLC Market Trends
Figure 23. Roche Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Beacon Pharma Limited Recent Developments and Future Plans
Figure 26. Drug International Limted Recent Developments and Future Plans
Figure 27. Incepta Pharmaceuticals Recent Developments and Future Plans
Figure 28. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Players in 2020
Figure 29. Targeted Drug ROS1 Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 31. Global Top 10 Players Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Type in 2020
Figure 34. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Share Forecast by Type (2021-2026)
Figure 35. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Application in 2020
Figure 36. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Share Forecast by Application (2021-2026)
Figure 37. North America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 38. North America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 39. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 40. United States Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 44. Europe Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 45. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 46. Germany Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 54. China Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 61. South America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 62. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source
世界のNSCLC用標的薬HER2阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug HER2 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…- 世界のNSCLC用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の乳がん用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 未分化リンパ腫キナーゼ阻害剤の世界市場 2019年版：種類別（クリゾチニブ、セリチニブ、塩酸アレクチニブ）、用途別（NSCLC、乳がん、大腸がん、神経芽細胞腫、卵巣がん、その他） Scope of the Report: The worldwide market for Anaplastic Lymphoma Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the A…
- 世界の腫瘍壊死因子阻害薬市場 2021：企業別、地域別、種類・用途別 The Tumor Necrosis Factor Inhibitors Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…